Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
The plant has a capacity for extraction of 2500 mt of poppy straw and 300 mt poppy gum per year
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Subscribe To Our Newsletter & Stay Updated
